A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: tucatinib
DRUG: trastuzumab
DRUG: bevacizumab
DRUG: cetuximab
DRUG: oxaliplatin
DRUG: leucovorin
DRUG: levoleucovorin
DRUG: fluorouracil

Sponsor

Seagen, a wholly owned subsidiary of Pfizer